Hepburn B
Division of Rheumatology, UMDNJ-Robert Wood Johnson Medical School, New Brunswick 08903.
J Rheumatol Suppl. 1988 Sep;16:40-2.
The disease modifying antirheumatic drugs (DMARD) used to treat rheumatoid arthritis (RA) are distinct from the nonsteroidal antiinflammatory drugs (NSAID) in their slow onset of antiinflammatory action, their lack of analgesic properties, their more frequent and severe toxicity, and in the opinion of some experts, their ability to produce more frequent remissions and slow the progression of erosions. New DMARD prospects include less toxic immune modulating agents, as well as NSAID/DMARD hybrids. Although currently available DMARD are considered primarily treatment for RA, sulfasalazine may be such a drug for B27 arthropathies as well. Future studies may lead to the development of agents that are specific modifiers of other rheumatic diseases, including lupus and scleroderma.
用于治疗类风湿关节炎（RA）的改善病情抗风湿药（DMARD）在抗炎作用起效缓慢、缺乏止痛特性、毒性更频繁且更严重，以及一些专家认为它们能更频繁地诱导病情缓解并减缓侵蚀进展方面，与非甾体抗炎药（NSAID）不同。新的DMARD前景包括毒性更低的免疫调节剂以及NSAID/DMARD混合制剂。尽管目前可用的DMARD主要被视为RA的治疗药物，但柳氮磺胺吡啶可能也是治疗B27关节炎的药物。未来的研究可能会开发出针对包括狼疮和硬皮病在内的其他风湿性疾病的特异性改善病情药物。
